Assessing the periprocedural magnitude of platelet count change in response to lusutrombopag

Background & Aims Despite limitations, platelet transfusion has been used to minimise bleeding risk in patients with thrombocytopaenia. Lusutrombopag is an oral, thrombopoietin receptor agonist approved for treatment of thrombocytopaenia associated with chronic liver disease in patients undergoing planned invasive procedures. This post-hoc analysis assessed the magnitude of platelet count change based on the integrated per-protocol population from 2 similar phase III multicentre, randomised, double-blind, placebo-controlled trials. Methods Adults with chronic liver disease-induced thrombocytopaenia and platelet count
Graphical abstract
Highlights • Thrombocytopaenia is common in patients with chronic liver disease. • Lusutrombopag increased platelet count ≥1.5-fold in most patients with chronic liver disease-induced thrombocytopaenia. • Lusutrombopag doubled platelet count in half of patients treated. • Lusutrombopag-induced platelet count increases (without platelet transfusion) lasted for 3 weeks.